Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy

Journal of Bone and Mineral Research

Volumn 30, Issue 3, 2015, Pages 539-549

  Moe, Sharon M ^a,b   Chen, Neal X ^a   Newman, Christopher L ^a,c   Organ, Jason M ^a,c   Kneissel, Michaela ^d   Kramer, Ina ^d   Gattone, Vincent H ^a,c   Allen, Matthew R ^a,c  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CKD MBD; FGF23; Parathyroid hormone; Renal osteodystrophy; Sclerostin; WNT

Indexed keywords

ANABOLIC AGENT; CALCIUM; DICKKOPF 1 PROTEIN; DRINKING WATER; MONOCLONAL ANTIBODY; PARATHYROID HORMONE; SCLEROSTIN; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTIBODY; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE MASS; BONE MINERALIZATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DRUG EFFICACY; EXPERIMENTAL RENAL FAILURE; GENE EXPRESSION; IMMUNOTHERAPY; KIDNEY FUNCTION; MALE; NONHUMAN; OSSIFICATION; OUTCOME ASSESSMENT; PERIMETRY; PERIOSTEUM; PLASMA CONCENTRATION-TIME CURVE; POROSITY; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RAT; RAT MODEL; REAL TIME POLYMERASE CHAIN REACTION; RENAL OSTEODYSTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; TRABECULAR BONE; ANIMAL; GENETIC MARKER; IMMUNOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBODIES; BONE MORPHOGENETIC PROTEINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENETIC MARKERS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RENAL OSTEODYSTROPHY;

EID: 84922932317     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2372     Document Type: Article

References (48)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBDWork Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76 Suppl113: S1-130. Available from: Http://kdigo.org/home/mineral-bone-disorder.
2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement fromKidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11): 1945-53.
3. Moe SM, Drueke T, Lameire N, Eknoyan G. Chronic kidney diseasemineral-bone disorder: A new paradigm. Adv Chronic Kidney Dis. 2007;14(1): 3-12.
4. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12): 2105-15.
5. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007;18(1): 59-68.
6. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: An analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4): 503-8.
7. Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19(7): 1430-8.
8. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8): 1829-35.
9. Sprague SM, Moe SM. Rebuttal: PTH-A particularly tricky hormone: Why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013;8(2): 321.
10. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299(4): F882-F89.
11. Rhee Y, Bivi N, Farrow E, et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone. 2011;49(4): 636-43.
12. Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte function. Bone. 2013;54(2): 250-7.
13. Cejka D, Jager-Lansky A, Kieweg H, et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012;27(1): 226-30.
14. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med. 2013;19(2): 179-92.
15. Marenzana M, Vugler A, Moore A, Robinson M. Effect of sclerostinneutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: A microCT study. Arthritis Res Ther. 2013;15(5): R125.
16. McGee-Lawrence ME, Ryan ZC, Carpio LR, Kakar S, Westendorf JJ, Kumar R. Sclerostin deficient mice rapidly heal bone defects by activating beta-catenin and increasing intramembranous ossification. Biochem Biophys Res Commun. 2013;441(4): 886-90.
17. Taut AD, Jin Q, Chung JH, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 2013;28(11): 2347-56.
18. Virk MS, Alaee F, Tang H, Ominsky MS, Ke HZ, Lieberman JR. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am. 2013;95(8): 694-701.
19. Williams BO. Insights into the mechanisms of sclerostin action in regulating bone mass accrual. J Bone Miner Res. 2014;29(1): 24-8.
20. McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single-and multipledose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014 Apr;29(4): 935-43.
21. Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6(4): 877-82.
22. Sabbagh Y, Graciolli FG, O'Brien S, et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012;27(8): 1757-72.
23. Allen MR, Chen NX, Gattone VH 2nd, et al. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int. 2013;24(4): 1471-81.
24. Allen MR, Chen NX, Gattone Ii VH, Moe SM. Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment. Am J Nephrol. 2013;38(6): 458-64.
25. Moe SM, Chen NX, Seifert MF, et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int. 2009;75(2): 176-84.
26. Moe SM, Radcliffe JS, White KE, et al. The pathophysiology of earlystage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res. 2011;26(11): 2672-81.
27. Moe SM, Chen NX, Newman CL, et al. A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res. 2014;29(4): 902-10.
28. Moe SM, Seifert MF, Chen NX, et al. R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKDMBD). Nephrol Dial Transplant. 2009 Aug;24(8): 2371-7.
29. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25(7): 1468-86.
30. Guo J, Liu M, Yang D, et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 2010;11(2): 161-71.
31. Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone. 2000;27(1): 13-20.
32. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67(5 Suppl): 61-70.
33. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2(6): 595-610.
34. Chen NX, O'Neill K, Chen X, Kiattisunthorn K, Gattone VH, Moe SM. Transglutaminase 2 accelerates vascular calcification in chronic kidney disease. Am J Nephrol. 2013;37(3): 191-8.
35. Ominsky MS, Li X, Asuncion FJ, et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res. 2008;23(5): 672-82.
36. Kostenuik PJ, Capparelli C, Morony S, et al. OPG and PTH-(1-34) have additive effects on bonedensity andmechanical strength in osteopenic ovariectomized rats. Endocrinology. 2001;142(10): 4295-304.
37. Nickolas TL, Stein EM, Dworakowski E, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013;28(8): 1811-20.
38. O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;3(8): E2942.
39. Rhee Y, Lee EY, Lezcano V, et al. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. J Biol Chem. 2013;288(41): 29809-20.
40. Li C, Xing Q, Yu B, et al. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. J Bone Miner Res. 2013;28(10): 2094-108.
41. Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006;281(33): 23698-711.
42. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res. 2010;25(11): 2427-37.
43. Fang Y, Ginsberg C, Seifert M, et al. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol. 2014 Aug;25(8): 1760-73.
44. Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2013;8(5): 819-23.
45. Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2014;99(1): 248-55.
46. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol. 2010;163(5): 833-7.
47. Ferreira JC, Ferrari GO, Neves KR, et al. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease-role of sclerostin? PLoS One. 2013;8(11): E79721.
48. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKDMBD therapy? Clin J Am Soc Nephrol. 2010;5(2): 286-91.